Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today reported financial results for the quarter and fiscal year ended December 31, 2007.

Total revenue for the fourth quarter of 2007 was $2.0 million, with a net loss of $8.8 million. Total revenue for the year ended December 31, 2007 was $9.7 million, with a net loss of $38.8 million. As of December 31, 2007, cash, cash equivalents and marketable securities totaled $47.7 million, and debt totaled $2.3 million. Net cash used in operating activities in 2007 was $34.5 million.

Recent Highlights

-- This week at the 39th Annual Meeting on Women's Cancer hosted by the Society for Gynecologic Oncology in Tampa, Florida, Sunesis presented positive interim results from the company's ongoing Phase 2 clinical trial of SNS-595, a novel naphthyridine analog, in advanced platinum-resistant ovarian cancer patients.
-- Sixty-five women have been enrolled and treated with single-agent

SNS-595 at a dose of 48 mg/m2 administered once every three weeks,

with the majority of these women having been enrolled since October.

Forty-five women have sufficient follow up to yield useful safety

results and 35 are evaluable for best response using GOG-RECIST

criteria.

-- In this trial, SNS-595 has demonstrated disease control (defined as

stable disease, partial response or complete response), with 31 of

35 of evaluable patients having best responses of stable disease or

better. Of
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Sept. 16, 2014 /PRNewswire-iReach/ -- Researchers found that ... identifies patients with bone fragility fracture when today,s ... people worldwide are at risk of fracture for ... bone strength test, the DEXA bone density scan. ... for Bone and Mineral Research Annual Conference (ASBMR) ...
(Date:9/16/2014)... Canada (PRWEB) September 16, 2014 According ... the Toronto affiliate of ITRA Global, new development in ... the Toronto city council approving another 755 storeys of ... it appears construction cranes will be dominating the Toronto ... seems to have an unquenchable thirst for new development. ...
(Date:9/15/2014)... 16, 2014 Cancer Immunotherapy ... Adoptive T-cell Therapies is a new market research ... the three principal types of therapeutics that have ... in cancer immunotherapy (which is often called "immuno-oncology") ... and Adoptive cellular immunotherapy. , The regular ...
(Date:9/15/2014)... patient has sepsis, a life-threatening condition in which bacteria ... too fast for antibiotics to help. A new device ... team at Harvard,s Wyss Institute for Biologically Inspired Engineering ... , "Even with the best current treatments, sepsis patients ... percent of the time," said Mike Super, Ph.D., Senior ...
Breaking Biology Technology:ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 2ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 3ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4
... 2011 BioSpecifics Technologies Corp. (Nasdaq: BSTC ... products, today announced that BioSpecifics, President, Tom Wegman, will ... Health Care Conference on Monday, March 7, 2011, at ... Boston, Massachusetts. A live webcast of the ...
... Novavax, Inc. (Nasdaq: NVAX ) announced today ... company,s headquarters in Rockville, Maryland, on Monday, March 7, ... to $179 million. The Office of Biomedical Advanced Research ... Assistant Secretary for Preparedness and Response at the U.S. ...
... New research from the University of Pennsylvania demonstrates a ... atomic-scale material that has promising applications in a variety ... Nobel Prize in Physics. As explained in a ... to create high-quality graphene that is just a single ...
Cached Biology Technology:Maryland Governor Martin O'Malley to Visit Novavax in Celebration of HHS-BARDA Contract Award 2Maryland Governor Martin O'Malley to Visit Novavax in Celebration of HHS-BARDA Contract Award 3Maryland Governor Martin O'Malley to Visit Novavax in Celebration of HHS-BARDA Contract Award 4Penn physicists develop scalable method for making graphene 2Penn physicists develop scalable method for making graphene 3
(Date:9/16/2014)... show its extravagant, colorful tail feathers in courtship of ... a special camera developed by an engineer at Washington ... swordtail fish choose their mates based on a similar ... at Austin used a bioinspired polarization camera developed by ... engineering at Washington University, to make the discovery. His ...
(Date:9/16/2014)... waters of Southeast Alaska to the white sand beaches ... and tourist towns, coastal residents around the U.S. share ... along political lines. That,s a primary finding of a ... this month in the journal Society & Natural ... differences from place to place to place. Each environment ...
(Date:9/16/2014)... ethical choices such as buying clothing not made in ... and bringing their own bags when they go shopping? ... of Consumer Research , ethical consumption is motivated by ... unethical practices into action. , "Advocates of ethical consumerism ... costs of the products they choose, but unfortunately only ...
Breaking Biology News(10 mins):Camera developed at WUSTL sheds light on mate choice of swordtail fish 2Politics divide coastal residents' views of environment, UNH research finds 2Politics divide coastal residents' views of environment, UNH research finds 3Why are consumers willing to spend more money on ethical products? 2
... land managers on the Olympic Peninsula joined in an ... the University of Washington to develop a set of ... for resiliency and sustainability in the face of a ... of vegetation, hydrology, roads, fish, and wildlife on the ...
... In the chemistry of the living world, a pair of ... genetic code, they provide all organisms with a mechanism for ... vital to living systems. Yet according to John ... Informatics, at Arizona State University,s Biodesign Institute, it may not ...
... databases is just the tip of the iceberg in online ... focus to social networks and today a number of Facebook ... and other armed groups that have been included in the ... in a new study conducted by Prof. Gabriel Weimann of ...
Cached Biology News:Partnership yields options for adapting to climate change on the Olympic Peninsula 2Simpler times: Did an earlier genetic molecule predate DNA and RNA? 2Simpler times: Did an earlier genetic molecule predate DNA and RNA? 3Simpler times: Did an earlier genetic molecule predate DNA and RNA? 4A 'friend' request from al-Qaida 2
Mouse monoclonal [0.N.305] to G protein alpha - BSA and Azide free ( Abpromise for all tested applications). Antigen: Partially purified G protein alpha from rat brain. Entrez GeneID: 2778 ...
Rabbit polyclonal to VEGF Receptor 2 (phospho Y1214) ( Abpromise for all tested applications). entrezGeneID: 3791 SwissProtID: P35968...
...
Guanine nucleotide-binding protein G(k), alpha subunit...
Biology Products: